IL6R and arthritic joint disease: To determine the therapeutic potential of combined IL-6/IL-21 signaling pathway blockade during experimental arthritis, mice with CIA were treated with anti-IL-6R antibodies and/or sIL-21R.Fc starting either from the day of immunization (day 0, early treatment), or from the day of the booster injection (day 21, late treatment).